Welcome to Paid Research Studies




  • Condition:   Myelodysplastic Syndromes
    Intervention:   Drug: LB-100
    Sponsor:   Lixte Biotechnology Holdings, Inc.
    Recruiting

  • Condition:   Myelodysplastic Syndromes
    Intervention:   Drug: Freeze-Dried Black Raspberry Powder
    Sponsor:   Ehab L Atallah
    Recruiting

  • Condition:   Myelodysplastic Syndromes
    Intervention:   Drug: 50 gm CIVI/24 hours x 5 days every 4 week
    Sponsors:   NYU Langone Health;   Perlmutter Cancer Center
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: 5-azacitidine
    Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: ATG;   Radiation: Total Marrow Irradiation;   Procedure: Stem Cell Product Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Illinois at Chicago
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia
    Interventions:   Drug: abaloparatide;   Drug: bevacizumab
    Sponsor:   University of Rochester
    Recruiting

  • Conditions:   Anemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Deferasirox;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   High-risk Myelodysplastic Syndrome
    Intervention:   Drug: SEL120
    Sponsors:   Selvita S.A.;   ICON plc
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Intervention:   Drug: ONC201
    Sponsor:   Vijaya Bhatt
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Intervention:  
    Sponsor:   University of Rochester
    Recruiting

  • Condition:   High Risk Myelodysplastic Syndrome
    Intervention:   Drug: Guadecitabine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Myelodysplastic Syndrome (MDS)
    Intervention:   Drug: CPX-351
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Myeloproliferative Neoplasm;   Acute Myeloid Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Ascorbic acid
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Conditions:   Aplastic Anemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Biological: Filgrastim;   Drug: Methylprednisolone;   Biological: Pegfilgrastim
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Progressive Disease
    Interventions:   Drug: CPI-613;   Drug: Hydroxychloroquine
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Myelodysplastic Syndromes
    Intervention:   Other: Peri-Transfusion QOL Assessment
    Sponsors:   Dana-Farber Cancer Institute;   Vera and Joseph Dresner Foundation
    Recruiting

  • Condition:   Myelodysplastic Syndromes(MDS)
    Intervention:  
    Sponsors:   PersImmune, Inc;   University of California, San Diego
    Recruiting

  • Conditions:   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Myelodysplastic Syndrome
    Interventions:   Drug: Belinostat;   Drug: Pevonedistat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Leukemia, Myeloid, Acute;   Leukemia, Relapsed Adult Acute Myeloid;   Myelodysplastic Syndromes, Previously Treated
    Interventions:   Drug: CPX-351;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit Anti-Human T-Lymphocyte Globulin;   Biological: Haplo-Cord Stem Cell Transplantation
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Intervention:   Biological: Daratumumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   High Risk Myelodysplastic Syndrome;   IPSS Risk Category Intermediate-1;   Myelodysplastic Syndrome
    Interventions:   Drug: Azacitidine;   Biological: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic;   Anemia, Refractory, With Excess of Blasts
    Intervention:   Drug: IGF/MTX
    Sponsor:   IGF Oncology, LLC
    Recruiting

  • Conditions:   Myelodysplasia;   Hematologic Malignancy
    Intervention:   Device: CliniMACS® TCRαβ/CD19 Combined Depletion System
    Sponsor:   Nationwide Children's Hospital
    Recruiting

  • Condition:   Myelodysplastic Syndrome
    Intervention:   Drug: ACE-011
    Sponsor:   Celgene
    Available

  • Condition:   Acute Myeloid Leukemia or Myelodysplastic Syndromes
    Intervention:   Drug: APR-246
    Sponsor:   Aprea Therapeutics AB
    Recruiting

  • Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: CPX-351;   Procedure: Research skin biopsy;   Procedure: Research blood draw;   Procedure: Research bone marrow aspirate
    Sponsors:   Washington University School of Medicine;   Jazz Pharmaceuticals
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia AML;   Myelodysplastic Syndrome MDS
    Intervention:   Drug: Vidaza and Valproic Acid
    Sponsor:   Patrick Stiff
    Recruiting

  • Conditions:   Adult Myelodysplastic Syndrome;   Anemia;   Chronic Myelomonocytic Leukemia
    Interventions:   Drug: Eltrombopag Olamine;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
    Sponsors:   Amit Verma;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm
    Interventions:   Drug: Azacitidine;   Drug: BRD4 Inhibitor PLX51107
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndromes
    Intervention:   Other: Diet
    Sponsor:   University of Florida
    Recruiting

  • Condition:   Myelodysplastic Syndrome (MDS)
    Intervention:   Drug: CC-486
    Sponsor:   Celgene
    Available

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Myelodysplastic Syndrome
    Interventions:   Drug: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727;   Drug: IDH-1 Inhibitor FT-2102
    Sponsors:   Vanderbilt-Ingram Cancer Center;   Astex Pharmaceuticals;   Forma Therapeutics, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Device: Health Telemonitoring;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Supportive Care
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Azacitidine;   Drug: SL-401;   Drug: Venetoclax
    Sponsors:   Dana-Farber Cancer Institute;   Stemline Therapeutics, Inc.
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
    Intervention:   Drug: PRGN-3006 T Cells
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Precigen, Inc
    Recruiting

  • Conditions:   Chronic Myelomonocytic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory High Risk Myelodysplastic Syndrome
    Interventions:   Drug: Cytarabine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Prexasertib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsor:   Hackensack Meridian Health
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Gemtuzumab Ozogamicin
    Sponsor:   New York Medical College
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Gemtuzumab Ozogamicin
    Sponsor:   New York Medical College
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: ONC201;   Drug: Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   Oncoceutics, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Edetate Calcium Disodium;   Dietary Supplement: Multivitamin;   Drug: Succimer
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory High Risk Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Drug: Decitabine;   Biological: Pembrolizumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia;   Blasts 20-30 Percent of Bone Marrow Nucleated Cells;   Blasts 20-30 Percent of Peripheral Blood White Cells;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   IPSS Risk Category Intermediate-2;   Myelodysplastic Syndrome
    Interventions:   Drug: Azacitidine;   Drug: Glutaminase Inhibitor CB-839
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Higher Risk Myelodysplastic Syndrome
    Interventions:   Drug: Nivolumab;   Drug: Stage 1 Arm 1: Low dose Cyclophosphamide (CTX);   Drug: Stage 1 Arm 2: Low dose Cyclophosphamide (CTX);   Drug: Stage 2: Low dose Cyclophosphamide (CTX)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 10 Percent of Peripheral Blood White Cells;   CD33 Positive;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Gemtuzumab Ozogamicin;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Blasts 20 Percent or More of Bone Marrow Nucleated Cells;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory High Risk Myelodysplastic Syndrome
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Idarubicin;   Drug: Quizartinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS)
    Intervention:   Drug: N-803
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Blasts 10-19 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   High Risk Chronic Myelomonocytic Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Chronic Myelomonocytic Leukemia;   Refractory High Risk Myelodysplastic Syndrome
    Intervention:   Drug: Liposome-encapsulated Daunorubicin-Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   High Risk Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Mixed Phenotype Acute Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Pretargeted Radioimmunotherapy;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Device: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory High Risk Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Drug: Ibrutinib;   Drug: Lenalidomide
    Sponsors:   Brian Jonas;   Pharmacyclics LLC.;   Celgene;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Myelodysplastic Syndromes
    Intervention:   Drug: TEW-7197
    Sponsor:   MedPacto, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: sapacitabine and decitabine (Part 1 - completed);   Drug: sapacitabine and venetoclax (Part 2 - recruiting)
    Sponsors:   Cyclacel Pharmaceuticals, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Neoplasms;   Myelodysplastic Syndromes;   Lymphomas
    Intervention:   Drug: Bortezomib plus Clofarabine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: rivogenlecleucel & rimiducid;   Drug: rimiducid;   Drug: Cyclophosphamide
    Sponsor:   Bellicum Pharmaceuticals
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cladribine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Decitabine
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Biological: haplo-identical cells (donor);   Biological: umbilical cord blood unit (CBU)
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Intervention:   Biological: MultiTAA-specific T cells
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine;   American Society for Blood and Marrow Transplantation (ASBMT);   Cancer Prevention Research Institute of Texas
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Hematopoietic Stem Cell Transplant (HSCT)
    Interventions:   Drug: Reduced-Intensity Conditioning Regimen;   Drug: Myeloablative Conditioning Regimen
    Sponsor:   Randy Windreich
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia, Ph1-Positive;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: BP1001 (varying dose);   Drug: BP1001 (fixed dose);   Drug: Dasatinib
    Sponsor:   Bio-Path Holdings, Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myelofibrosis Transformation in Essential Thrombocythemia;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis
    Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Drug: Ruxolitinib Phosphate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   AML;   MDS
    Interventions:   Drug: CYC065;   Drug: Venetoclax
    Sponsors:   Cyclacel Pharmaceuticals, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   AML, Adult;   Myelodysplastic Syndromes;   ALL, Adult;   CML, Refractory;   CLL, Refractory
    Intervention:   Drug: CYC140
    Sponsors:   Cyclacel Pharmaceuticals, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Blasts 20-30 Percent of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   IDH2 Gene Mutation;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory High Risk Myelodysplastic Syndrome
    Interventions:   Drug: Azacitidine;   Drug: Enasidenib;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Celgene
    Recruiting

  • Conditions:   Severe Aplastic Anemia (SAA);   Hypo-Plastic Myelodysplastic Syndrome (MDS)
    Intervention:   Procedure: haplo-identical transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   AML;   Advanced Myelodysplastic Syndromes;   MDS
    Interventions:   Drug: Pevonedistat;   Drug: Cytarabine
    Sponsors:   Justin Watts;   Takeda
    Recruiting

  • Conditions:   High-risk Myelodysplastic Syndromes;   Acute Myelogenous Leukemia;   Systemic Mastocytosis;   Mast Cell Leukemia
    Interventions:   Drug: 161533 Trike™ Phase I;   Drug: 161533 Trike™ Phase II
    Sponsor:   GT Biopharma, Inc.
    Not yet recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia;   de Novo Myelodysplastic Syndrome;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate;   Drug: Mitoxantrone;   Drug: Sorafenib
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 10 Percent of Peripheral Blood White Cells;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   TP53 Gene Deletion;   TP53 Gene Mutation
    Interventions:   Drug: Decitabine;   Drug: Quizartinib;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Blasts 30 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Refractory Anemia
    Interventions:   Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Poly ICLC
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Celldex Therapeutics
    Recruiting

  • Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Other: Quality-of-Life Assessment
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
    Interventions:   Drug: Atezolizumab;   Drug: Guadecitabine
    Sponsors:   University of Southern California;   National Cancer Institute (NCI);   Van Andel Research Institute
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Blasts 10-20 Percent of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   High Risk Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Recurrent Mixed Phenotype Acute Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Refractory High Risk Myelodysplastic Syndrome;   Refractory Mixed Phenotype Acute Leukemia;   TP53 Gene Deletion;   TP53 Gene Mutation
    Interventions:   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Acute Myeloid Leukemia With Variant MLL Translocations;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Chemotherapy-Related Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Gene Mutation;   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Allogeneic Natural Killer Cell Line NK-92;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: AZD6738
    Sponsors:   Massachusetts General Hospital;   AstraZeneca
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   High Risk Acute Myeloid Leukemia;   High Risk Myelodysplastic Syndrome;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome
    Interventions:   Biological: Donor Lymphocytes;   Drug: Guadecitabine;   Other: Laboratory Biomarker Analysis
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Gene Mutations;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Blasts 10 Percent or More of Peripheral Blood White Cells;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Gilteritinib;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
    Interventions:   Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia
    Intervention:   Drug: Pembrolizumab
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   de Novo Myelodysplastic Syndrome;   High Risk Myelodysplastic Syndrome;   Inv(16);   Myelodysplastic Syndrome With Excess Blasts;   t(16;16);   t(8;21);   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Biological: Filgrastim-sndz;   Drug: Fludarabine Phosphate;   Drug: Gemtuzumab Ozogamicin;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Myelodysplasia
    Intervention:   Device: Alpha Beta T cell depletion
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
    Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Hypo-Plastic MDS;   Myelodysplastic Syndrome (MDS)
    Intervention:   Biological: CordIn
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Myelodysplastic Syndrome (MDS)
    Intervention:   Drug: AMV564 14-Day CIV
    Sponsor:   Amphivena Therapeutics, Inc.
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Leukemia;   Lymphoma;   Myelodysplastic Syndromes
    Interventions:   Drug: Nivolumab;   Drug: Tocilizumab
    Sponsor:   Medical College of Wisconsin
    Recruiting

  • Conditions:   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Biological: Palifermin;   Biological: Lupron;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total-Body Irradiation (TBI);   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Degarelix
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Swedish Orphan Biovitrum
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia
    Intervention:   Biological: G-CSF mobilized CD34+ selected cells for transplantation
    Sponsor:   Emory University
    Available

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Atorvastatin;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsor:   Loyola University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   High Risk Myelodysplastic Syndrome;   Myeloid Sarcoma;   Myeloproliferative Neoplasm;   Philadelphia Chromosome Positive
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Dexrazoxane Hydrochloride;   Drug: Gemtuzumab Ozogamicin;   Drug: Idarubicin
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome (MDS);   Lymphoma
    Intervention:   Biological: Cord Blood Units
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   National Institute of Allergy and Infectious Diseases (NIAID);   National Cord Blood Program, New York Blood Center
    Recruiting

  • Conditions:   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Idarubicin;   Drug: Idarubicin Hydrochloride;   Biological: Pegfilgrastim;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Milademetan;   Drug: AZA
    Sponsor:   Daiichi Sankyo, Inc.
    Recruiting

  • Conditions:   Fanconi Anemia;   Severe Aplastic Anemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Total Body Irradiation (TBI) (Plan 1);   Drug: Cyclophosphamide (CY) (Plan 1);   Drug: Fludarabine (FLU);   Drug: Methylprednisolone (MP);   Device: Donor mobilized PBSC infusion;   Drug: G-CSF;   Drug: Cyclophosphamide (CY) (Plan 2);   Drug: Rituximab
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Fanconi Anemia;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Anti-Thymocyte Globulin (Rabbit);   Device: The CliniMACS device;   Drug: G-CSF
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Pediatric Brain Tumor Consortium
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Mixed Phenotype Acute Leukemia;   Juvenile Myelomonocytic Leukemia
    Interventions:   Drug: Vorinostat;   Drug: Azacitidine Injection
    Sponsor:   Johns Hopkins All Children's Hospital
    Recruiting

  • Conditions:   AML;   NHL;   Hodgkin Disease;   All;   Myelodysplastic Syndrome
    Intervention:   Drug: Hyperbaric oxygen
    Sponsor:   University of Rochester
    Recruiting

  • Conditions:   Relapsed Acute Myeloid Leukemia (AML);   Refractory Acute Myeloid Leukemia (AML);   High-risk Myelodysplastic Syndrome (MDS)
    Intervention:   Drug: PLX2853
    Sponsor:   Plexxikon
    Recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Pevonedistat;   Other: Pharmacological Study
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neoplasms;   Adenomatous Polyposis Coli;   Neurofibroma, Plexiform;   Myelodysplastic Syndromes
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Azacitidine;   Drug: Ibrutinib
    Sponsors:   Brian Jonas;   Pharmacyclics LLC.
    Recruiting

  • Conditions:   Myelodysplastic Syndrome (MDS);   Hematologic Neoplasms;   Hematologic Diseases;   Severe Aplastic Anemia
    Intervention:   Drug: Cord Blood Transplant
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hematologic Malignancy
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Total Marrow Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Stem Cell Transplant Candidate;   Acute Myeloid/Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Lymphoproliferative Disorders
    Intervention:   Biological: Cellular therapy product
    Sponsor:   Case Comprehensive Cancer Center
    Not yet recruiting

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Cytokine-induced killer cells;   Biological: IL-2;   Drug: ALT-803;   Procedure: Peripheral blood for correlative studies;   Procedure: Bone marrow for correlative studies
    Sponsors:   Washington University School of Medicine;   American Society of Clinical Oncology;   American Society of Hematology;   Gabrielle's Angel Foundation;   The Leukemia and Lymphoma Society;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Hematopoietic Cell Transplant
    Intervention:   Behavioral: ePRO survey
    Sponsors:   Center for International Blood and Marrow Transplant Research;   Medical College of Wisconsin
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Acute Lymphatic Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine;   Radiation: Total Marrow Irradiation (TMI)
    Sponsors:   Naoyuki G. Saito, M.D., Ph.D.;   Indiana University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: EAGD T-cell infusion (Phase I);   Drug: EAGD T-cell infusion (Expansion)
    Sponsors:   University of Alabama at Birmingham;   Incysus
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Therapy-Related Myeloid Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Radiation: total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Clofarabine;   Procedure: (CliniMACS) T-cell depleted PBSC Transplant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Neoplasms
    Interventions:   Drug: GSK3326595;   Drug: 5-azacitidine;   Drug: Best available care
    Sponsor:   GlaxoSmithKline
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Acute Leukemia
    Intervention:   Biological: OrcaGraft
    Sponsor:   Orca Biosystems, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Myelodysplastic Syndromes;   Other Acute Leukemias
    Interventions:   Biological: Unmanipulated Umbilical Cord Blood (UCB);   Biological: AB-110
    Sponsors:   Angiocrine Bioscience;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Myeloproliferative Neoplasm
    Interventions:   Drug: Azacitidine Subcutaneous Injection or Intravenous Infusion;   Drug: Pevonedistat Infusion;   Procedure: Bone Marrow Biopsy & Aspirate
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia-1;   Cytopenia
    Interventions:   Dietary Supplement: Vitamin C (ascorbic acid);   Other: Placebo
    Sponsors:   Rigshospitalet, Denmark;   Van Andel Research Institute;   University of Southern California;   Imperial College London;   University of Copenhagen;   Herlev Hospital;   Zealand University Hospital;   Technical University of Denmark
    Recruiting

  • Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: Imetelstat;   Drug: Placebo
    Sponsor:   Geron Corporation
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cord Blood Transplant Recipient;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm
    Intervention:   Biological: Recombinant Interleukin-7
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Myelodysplastic Syndromes (MDS)
    Intervention:   Other: Therapeutic
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Adult Acute Myeloid Leukemia;   Relapsed Adult Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia Arising From Previous Myeloproliferative Disorder
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: 8-chloro-adenosine
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Myelodysplastic Syndromes (MDS)
    Interventions:   Drug: Azacitidine;   Drug: Venetoclax
    Sponsors:   AbbVie;   Genentech, Inc.
    Recruiting

  • Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: MBG453;   Drug: Placebo;   Drug: Hypomethylating agents
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML);   MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable);   Hematopoietic Stem Cell Transplant
    Interventions:   Drug: Venetoclax;   Drug: Fludarabine;   Drug: Busulfan
    Sponsor:   Jacqueline Garcia, MD
    Recruiting

  • Condition:   Myelodysplastic Syndromes (MDS)
    Interventions:   Drug: venetoclax;   Drug: azacitidine
    Sponsors:   AbbVie;   Celgene;   Genentech, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Neoplasms;   Chronic Myelomonocytic Leukemia;   Myelofibrosis
    Interventions:   Drug: Ipilimumab;   Biological: CD25hi Treg depleted DLI
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting

  • Condition:   Myelodysplastic Syndromes
    Intervention:   Drug: ASTX727 LD
    Sponsor:   Astex Pharmaceuticals
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
    Interventions:   Biological: GVAX;   Biological: Placebo Vaccine;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Other: Haploidentical Stem Cell Transplantation
    Sponsor:   Loyola University
    Recruiting

  • Conditions:   Blasts 21-30 Percent of Bone Marrow Nucleated Cells;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
    Interventions:   Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center;   Fred Hutchinson Cancer Research Center
    Recruiting

  • Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
    Intervention:   Drug: JNJ-67571244
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

  • Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
    Intervention:   Drug: CC-90009
    Sponsor:   Celgene
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: SY-1425 (tamibarotene);   Drug: azacitidine;   Drug: Daratumumab
    Sponsor:   Syros Pharmaceuticals
    Recruiting

  • Conditions:   Adult Acute Myeloid Leukemia;   Adult Myelodysplastic Syndrome
    Intervention:   Drug: Chemotherapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes (MDS);   Acute Myelogenous Leukemia (AML)
    Intervention:   Drug: low dose 5'-azacitidine
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
    Intervention:   Drug: H3B-8800
    Sponsors:   H3 Biomedicine Inc.;   Eisai Inc.
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute
    Interventions:   Drug: Azacitidine;   Drug: Pevonedistat
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndromes;   Non-Hodgkin Lymphoma;   Hodgkin Disease
    Interventions:   Procedure: Stem cell transplantation;   Drug: Itacitinib;   Other: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT);   Other: Human Activity Profile
    Sponsors:   Washington University School of Medicine;   Incyte Corporation
    Recruiting

  • Conditions:   Myeloid Malignancies;   Acute Myelogenous Leukemia;   Chronic Myelogenous Leukemia;   Myeloproliferative Disorders;   Myelodysplastic Syndrome
    Interventions:   Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);   Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
    Sponsor:   Hackensack Meridian Health
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Erythroid Leukemia;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blasts Under 20 Percent of Bone Marrow Nucleated Cells;   Blasts Under 20 Percent of Peripheral Blood White Cells;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Aldesleukin;   Biological: Allogeneic CD56-positive CD3-negative Natural Killer Cells;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Risk Myelodysplastic Syndrome;   HLA-A2 Positive Cells Present;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Myelofibrosis;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Myelodysplastic Syndromes (MDS)
    Intervention:   Combination Product: Alvocidib Plus Decitabine
    Sponsor:   Tolero Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia/Myelodysplastic Syndrome;   Multiple Myeloma (MM)
    Intervention:   Biological: NKR-2 cells
    Sponsor:   Celyad (formerly named Cardio3 BioSciences)
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
    Intervention:  
    Sponsor:   Celgene
    Recruiting

  • Condition:   MDS
    Interventions:   Drug: APR-246 + azacitidine;   Drug: Azacitidine
    Sponsor:   Aprea Therapeutics AB
    Recruiting

  • Conditions:   Acute Myeloid Leukaemia (AML);   Myelodysplastic Syndrome (MDS)
    Intervention:   Drug: S64315
    Sponsors:   Institut de Recherches Internationales Servier;   ADIR, a Servier Group company
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Radiation: radiation therapy;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm
    Interventions:   Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematological Malignancy;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Myelodysplastic Syndromes;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Biological: Cord blood stem cells;   Drug: Valproic Acid;   Drug: Fludarabine;   Drug: cytoxan;   Drug: Thiotepa;   Biological: TBI
    Sponsor:   Alla Keyzner
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Cancer Fatigue;   Lymphoma;   Secondary Acute Myeloid Leukemia
    Interventions:   Behavioral: Cognitive Behavior Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Device: 3'-deoxy-3'-[18F]fluorothymidine
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   High-risk Myelodysplastic Syndrome
    Intervention:   Drug: BP1001 in combination with decitabine
    Sponsor:   Bio-Path Holdings, Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   Leukocyte Disorders;   Anemia Due to Intrinsic Red Cell Abnormality
    Intervention:   Biological: CD34+ enriched, T Cell Depleted donor stem cell product
    Sponsor:   University of California, San Francisco
    Available

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Gene Mutations;   Aplastic Anemia;   B-Cell Non-Hodgkin Lymphoma;   CD40 Ligand Deficiency;   Chronic Granulomatous Disease;   Chronic Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Congenital Amegakaryocytic Thrombocytopenia;   Congenital Neutropenia;   Congenital Pure Red Cell Aplasia;   Glanzmann Thrombasthenia;   Immunodeficiency Syndrome;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Plasma Cell Myeloma;   Polycythemia Vera;   Recurrent Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Severe Aplastic Anemia;   Shwachman-Diamond Syndrome;   Sickle Cell Disease;   T-Cell Non-Hodgkin Lymphoma;   Thalassemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Erythroid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Hematopoietic and Lymphoid Cell Neoplasm;   Human Immunodeficiency Virus Positive;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Non-Hodgkin Lymphoma;   Refractory Anemia
    Interventions:   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Other: Cellular Therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Not yet recruiting

  • Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Hematopoietic Cell Transplant Recipient;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Refractory Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Decitabine;   Biological: Ipilimumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   JAK2 Gene Mutation;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   RAS Family Gene Mutation;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hematologic Malignancy;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome;   TP53 Gene Mutation
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Irradiated Allogeneic Cells
    Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blasts 0.1 Percent or More of Bone Marrow Nucleated Cells;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Recurrent Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Drug: Pevonedistat;   Drug: Therapeutic Hydrocortisone
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Bilineal Leukemia;   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Drug: Azacitidine;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Azacitidine (AZA) Days 1 - 3;   Drug: Decitabine (DAC);   Other: Best Supportive Care (BSC);   Drug: Azacitidine (AZA) Days 1 - 5
    Sponsors:   M.D. Anderson Cancer Center;   MDS Consortium
    Recruiting

  • Conditions:   HLA-A*0201 HA-1 Positive Cells Present;   Juvenile Myelomonocytic Leukemia;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Undifferentiated Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Donor;   Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm;   Recurrent Myelodysplastic Syndrome;   Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm;   Refractory Myelodysplastic Syndrome;   Acute Undifferentiated Leukemia;   Blast Cells Present;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Minimal Residual Disease;   Mixed Phenotype Acute Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia
    Interventions:   Biological: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Alex's Lemonade Stand Foundation;   National Cancer Institute (NCI);   The Leukemia and Lymphoma Society
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   AML - Acute Myeloid Leukemia;   MDS (Myelodysplastic Syndrome);   Mixed Phenotype Acute Leukemia;   NHL - Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   ALL
    Intervention:   Biological: T-allo10
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Donor;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aplastic Anemia;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Hu5F9-G4;   Drug: Azacitidine
    Sponsors:   Forty Seven, Inc.;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   MDS;   Refractory Anemia With Excess Blasts;   RAEB
    Interventions:   Drug: rigosertib;   Drug: Any approved or standard-of-care therapy;   Drug: best supportive care (BSC)
    Sponsor:   Onconova Therapeutics, Inc.
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma;   Hematopoietic Cell Transplant Recipient
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   MDS
    Interventions:   Procedure: Allogeneic Hematopoietic Cell Transplant;   Procedure: Hypomethylating Therapy / Best Supportive Care
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: FT-2102;   Drug: Azacitidine;   Drug: Cytarabine
    Sponsor:   Forma Therapeutics, Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Radiation: Radiation;   Drug: Cyclophosphamide;   Biological: Donor Lymphocyte Infusion (DLI);   Biological: Haploidentical Stem Cell Transplantation
    Sponsors:   Northwell Health;   New York Blood Center
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Juvenile Myelomonocytic Leukemia (JMML);   Acute Lymphoblastic Leukemia (ALL);   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Combination Product: ITMHA;   Drug: Idarubicin;   Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Erwinia asparaginase;   Drug: Sorafenib;   Drug: G-CSF;   Drug: Dexrazoxane;   Biological: Stem Cell Transplant
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorder;   Chronic Lymphocytic Leukemia;   B-cell Lymphoma;   T-cell Lymphoma;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Chronic Myelomonocytic Leukemia
    Interventions:   Radiation: Total body irradiation (TBI);   Drug: Anti-thymocyte globulin (ATG);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Radiation: Total lymphoid irradiation (TLI)
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Myeloproliferative Syndromes;   Plasma Cell Myeloma;   Colon Carcinoma;   Adenocarcinoma of Rectum;   Soft Tissue Sarcoma;   Ewing's Sarcoma;   Rhabdomyosarcoma
    Interventions:   Biological: Natural Killer (NK) Cells;   Biological: ALT803
    Sponsor:   David Wald
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Acute Lymphoblastic Leukemia;   Mixed Lineage Leukemia;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   Juvenile Myelomonocytic Leukemia
    Intervention:   Device: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Leukemia
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: Filgrastim
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Lymphoma,Non-Hodgkin;   Lymphoma, Hodgkin;   Lymphoma, Follicular;   Marginal Zone Lymphoma;   Large Cell Lymphoma;   Mantle-Cell Lymphoma;   Gray Zone Lymphoma;   Burkitt Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Cyclophosphamide
    Sponsor:   University of Arizona
    Recruiting

  • Conditions:   AML;   MDS
    Intervention:   Biological: NKR-2
    Sponsors:   Celyad (formerly named Cardio3 BioSciences);   IQVIA Ltd
    Recruiting

  • Conditions:   Leukemia, Lymphoid;   Leukemia, Myeloid;   Myelodysplastic Syndromes;   Myelofibrosis;   Lymphoma, Malignant;   Multiple Myeloma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Biological: Rabbit ATG;   Drug: Methotrexate
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Acute Bilineal Leukemia;   Acute Biphenotypic Leukemia;   Chronic Myelomonocytic Leukemia;   IDH2 Gene Mutation;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Enasidenib Mesylate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Immune Deficiency Disorder;   Congenital Hematological Disorder;   Metabolism Disorder;   Aplastic Anemia;   Myelodysplastic Syndromes;   Chronic Leukemia;   Lymphoma;   Multiple Myeloma;   Solid Tumor
    Interventions:   Radiation: Total Body Irradiation 1200 cGy;   Radiation: Total Body Irradiation 200 cGy;   Drug: Cyclophosphamide;   Drug: Mesna;   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan
    Sponsor:   University of Rochester
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Dysplasia;   Essential Thrombocythemia;   FGFR1 Gene Rearrangement;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid Neoplasm;   Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm, Unclassifiable;   Overt Primary Myelofibrosis;   PDGFRA Gene Rearrangement;   PDGFRB Gene Rearrangement;   Polycythemia Vera;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Prefibrotic/Early Primary Myelofibrosis
    Interventions:   Drug: Azacitidine;   Drug: Pevonedistat;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute;   Renal Insufficiency;   Hepatic Impairment
    Interventions:   Drug: Azacitidine;   Drug: Pevonedistat
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegalovirus Positive;   Donor;   Hematopoietic Cell Transplant Recipient;   Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Myelofibrosis;   Hematopoietic and Lymphoid Cell Neoplasm
    Intervention:   Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegalovirus Positive;   Hematopoietic Cell Transplant Recipient;   Hodgkin Lymphoma;   Lymphadenopathy;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma
    Interventions:   Drug: Letermovir;   Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine;   Other: Placebo
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Hematologic Diseases;   Acute Myeloid Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia - Chronic Phase;   Chronic Myelogenous Leukemia, Accelerated Phase;   Chronic Myelogenous Leukemia, Blastic Phase;   Myelodysplastic Syndromes;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B Cell Lymphoma;   Non Hodgkin Lymphoma;   Graft Vs Host Disease;   Graft-versus-host-disease
    Interventions:   Drug: Vorinostat;   Procedure: Blood and Marrow Transplant (BMT);   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Bone Marrow Failure;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Follicular Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia;   Non-Hodgkin Lymphoma;   Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Cytokine-treated Veto Cells;   Drug: Fludarabine;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Leukemia, Myeloid;   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes;   Preleukemia;   Bone Marrow Diseases;   Hematologic Diseases
    Interventions:   Drug: Decitabine;   Drug: PDR001;   Drug: MBG453
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Rhabdomyosarcoma;   Ewing Sarcoma;   Primitive Neuroectodermal Tumor;   Osteosarcoma;   Neuroblastoma
    Interventions:   Procedure: TCRαβ+/CD19+ depleted Haploidentical HSCT;   Drug: Zoledronate
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplant Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)
    Interventions:   Drug: FG-4592;   Drug: Placebo
    Sponsors:   FibroGen;   AstraZeneca
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Brain Glioblastoma;   Estrogen Receptor Negative;   Extensive Stage Small Cell Lung Carcinoma;   Head and Neck Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Limited Stage Small Cell Lung Carcinoma;   Myelodysplastic Syndrome;   Progesterone Receptor Negative;   Progressive Disease;   Recurrent Carcinoma;   Stage II Pancreatic Cancer;   Stage II Rectal Cancer;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage III Colon Cancer;   Stage III Esophageal Cancer;   Stage III Gastric Cancer;   Stage III Non-Small Cell Lung Cancer;   Stage III Ovarian Cancer;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Skin Melanoma;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Bladder Cancer;   Stage IV Bone Sarcoma;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IV Soft Tissue Sarcoma;   Stage IVA Bone Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Bone Sarcoma;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Procedure: Supportive Care;   Other: Survey Administration
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   B-Cell Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Therapeutic Allogeneic Lymphocytes;   Radiation: Total Nodal Irradiation
    Sponsors:   Robert Lowsky;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Minimal Residual Disease;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
    Interventions:   Biological: Daratumumab;   Procedure: Donor Lymphocyte Infusion;   Other: Laboratory Biomarker Analysis
    Sponsors:   Sumithira Vasu;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Lymphoid Leukemia;   Lymphoma;   Leukemia;   Myeloma;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndromes;   Recurrent Acute Myeloid Leukemia, Adult;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia;   Acute Myelogenous Leukemia
    Interventions:   Drug: mycophenolate mofetil;   Biological: Sargramostim;   Biological: Filgrastim
    Sponsors:   Virginia Commonwealth University;   Massey Cancer Center
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Germ Cell Neoplasms;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immunodeficiency Diseases
    Intervention:  
    Sponsor:   Wake Forest University Health Sciences
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS);   NK-Cell Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma (NHL);   Juvenile Myelomonocytic Leukemia (JMML);   Chronic Myeloid Leukemia (CML)
    Interventions:   Drug: Cyclophosphamide;   Biological: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Biological: G-csf;   Drug: Mesna;   Device: CliniMACS;   Biological: ATG (rabbit);   Drug: Blinatumomab;   Biological: TCRα/β+;   Biological: CD19+;   Biological: CD45RA-depleted DLI
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Acute Bilineal Leukemia;   Minimal Residual Disease;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloproliferative Neoplasm;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic Syndrome
    Interventions:   Biological: Rivogenlecleucel;   Drug: Rimiducid
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   Bellicum Pharmaceuticals
    Not yet recruiting

  • Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Angioimmunoblastic T-cell Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Plasma Cell Myeloma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Angioimmunoblastic T-cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Refractory Plasma Cell Myeloma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Biological Therapy;   Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Single Photon Emission Computed Tomography
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Monoclonal Gammopathy of Undetermined Significance (MGUS);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic-Myeloproliferative Diseases;   Hematological Malignancies;   B-cell Malignancy, Low-grade;   Myelodysplastic Syndrome With Low-grade Lesions;   IgG Monoclonal Gammopathy of Uncertain Significance;   Smoldering Multiple Myeloma;   Waldenstrom Macroglobulinemia
    Intervention:  
    Sponsors:   Dana-Farber Cancer Institute;   The Leukemia and Lymphoma Society
    Recruiting

  • Conditions:   Myeloid Leukemia, Chronic;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes (MDS);   Lymphoma, Non-Hodgkin;   Acute Lymphoblastic Leukemia (ALL);   Myeloproliferative Syndrome;   Acute Myeloid Leukemia;   Acute Leukemia;   Chronic Myelogenous Leukemia
    Intervention:   Biological: Conventional T cells (Tcon) and Regulatory T cells (Treg)
    Sponsors:   Everett Meyer;   National Institutes of Health (NIH)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS;   Drug: Sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome
    Interventions:   Biological: ATIR101;   Drug: Cyclophosphamide;   Procedure: T-cell depleted HSCT from a related, haploidentical donor;   Procedure: T-cell replete HSCT from a related, haploidentical donor
    Sponsor:   Kiadis Pharma
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Cytopenia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm;   Trisomy 21;   Trisomy 21 Mosaicism
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematological Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Myelogenous Leukemia (CML);   Myelodysplastic Syndrome (MDS);   Lymphoma;   Acute Leukemia
    Interventions:   Drug: NiCord® (omidubicel);   Other: Cord Blood Unit
    Sponsor:   Gamida Cell ltd
    Recruiting

  • Conditions:   Hematologic Malignancy;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes
    Intervention:   Drug: CPX-351
    Sponsor:   Jazz Pharmaceuticals
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
    Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Myelodysplastic Syndrome
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Ann Arbor Stage I Burkitt Lymphoma;   Ann Arbor Stage I Non-Hodgkin Lymphoma;   Ann Arbor Stage II Burkitt Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage III Burkitt Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Burkitt Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   High Risk Acute Myeloid Leukemia;   Progressive Disease;   Refractory Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes (MDS);   Beta-thalassemia;   Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
    Intervention:   Drug: Luspatercept
    Sponsor:   Celgene
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia in Relapse;   Acute Myelogenous Leukemia, Relapsed, Adult;   Acute Myelogenous Leukemia, Adult;   Acute Myelogenous Leukemia;   High Risk Myelodysplasia
    Intervention:   Drug: APTO-253
    Sponsor:   Aptose Biosciences Inc.
    Recruiting

  • Conditions:   High Risk Myelodysplastic Syndrome;   IDH1 NP_005887.2:p.R132X;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Ivosidenib;   Other: Pharmacokinetic Study;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Therapy-Related Acute Myeloid Leukemia
    Intervention:   Drug: CPX-351
    Sponsor:   Jazz Pharmaceuticals
    Recruiting

  • Conditions:   Relapsed/Refractory Advanced Solid Tumors;   Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma;   Relapsed/Refractory Myelodysplasia;   Relapsed/Refractory Myelofibrosis
    Intervention:   Drug: PRT543
    Sponsor:   Prelude Therapeutics
    Recruiting

  • Conditions:   Newly Diagnosed Acute Myeloid Leukemia (AML);   Untreated AML;   AML Arising From Myelodysplastic Syndrome (MDS);   Leukemia, Myeloid, Acute
    Interventions:   Drug: AG-120 (ivosidenib) with Azacitidine;   Drug: Placebo with Azacitidine
    Sponsor:   Agios Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Neoplasms;   Solid Tumor, Adult;   Non-Hodgkin Lymphoma;   Myelodysplastic Syndromes
    Intervention:   Drug: JNJ-64619178
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplasia;   Lymphoma
    Interventions:   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide;   Drug: Mycophenolate Mofetil;   Drug: Cyclophosphamide
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
    Recruiting

  • Conditions:   Recurrent, Refractory, or High Risk Leukemias;   Matched Targeted Therapy
    Intervention:   Genetic: Leukemia Profiling
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting

  • Conditions:   AML;   MDS
    Intervention:   Biological: APVO436
    Sponsor:   Aptevo Research and Development LLC
    Recruiting

  • Conditions:   Myelofibrosis;   Leukemia, Myelocytic, Acute;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelodysplastic Syndrome (MDS)
    Interventions:   Drug: CPI-0610;   Drug: Ruxolitinib
    Sponsors:   Constellation Pharmaceuticals;   The Leukemia and Lymphoma Society
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia;   Myeloproliferative Disorder;   Myelofibrosis;   Lymphoma;   Lymphoma, Non-Hodgkin;   Plasma Cell Disorder
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Drug: Tacrolimus;   Drug: cellcept;   Drug: g-csf;   Procedure: Peripheral Blood Transplant
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Hodgkin Lymphoma;   Lymphoid Leukemia;   Multiple Myeloma;   Myeloid Leukemia;   Monocytic Leukemia;   Non Hodgkin Lymphoma;   Myelodysplasia
    Intervention:   Drug: Intravenous (IV) and oral Vitamin C
    Sponsor:   Virginia Commonwealth University
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Hodgkin Lymphoma;   Adult Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   HLA-A*0201 Positive Cells Present;   Myelodysplastic Syndrome;   Adult Lymphoblastic Lymphoma;   Chronic Lymphocytic Leukemia;   Myelofibrosis;   Myeloproliferative Neoplasm
    Interventions:   Biological: CMVpp65-A*0201 peptide vaccine;   Other: Placebo;   Other: Laboratory Biomarker Analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blasts 20 Percent or More of Bone Marrow Nucleated Cells;   Blasts 5-19 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelofibrosis;   Philadelphia Chromosome Negative;   Polycythemia Vera;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Carboplatin;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematologic Malignancies;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Acute Graft-versus-host Disease
    Interventions:   Biological: ProTmune;   Biological: Control Arm
    Sponsor:   Fate Therapeutics
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 25 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM);   Drug: Tacrolimus;   Drug: Methotrexate;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC)
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Relapsed or Refractory Hematologic Malignancies;   Non-Hodgkin Lymphoma;   Richter Syndrome;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   T-cell Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Myelodysplastic Syndrome (MDS);   Cutaneous T-cell Lymphoma
    Interventions:   Drug: AZD5991;   Drug: AZD5991 + Venetoclax
    Sponsor:   AstraZeneca
    Recruiting

  • Condition:   GATA2 Deficancy
    Intervention:  
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Baylor College of Medicine;   UCSF Diabetes Center and Division of Infectious Diseases;   Department of Molecular and Cell Biology;   New York Genome Center
    Recruiting

  • Condition:   Bone Marrow Failure Syndromes
    Interventions:   Other: MRD-BMT with Fludarabine-based RIC for Acquired AA;   Other: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia;   Other: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Acquired Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Inherited Bone Marrow Failure Syndromes
    Intervention:   Device: CliniMACs
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Condition:   Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Intervention:   Drug: Coversin
    Sponsor:   AKARI Therapeutics
    Recruiting

  • Conditions:   Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
    Interventions:   Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Diamond Blackfan Anemia;   Dyskeratosis Congenita;   Fanconi Anemia;   Shwachman Diamond Syndrome;   Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Paroxysmal Nocturnal Hemoglobinuria
    Intervention:  
    Sponsor:   Alexion Pharmaceuticals
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Non-hodgkin Lymphoma;   Hodgkin Lymphoma;   Acquired Aplastic Anemia;   Sickle Cell Disease
    Intervention:   Other: Donor Search Prognosis Score
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program;   Medical College of Wisconsin
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis;   Biological: Haplo HCT ≥55 and < 65 years old;   Biological: Haplo HCT ≥65 and ≤75 years old
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   GATA2;   Immunodeficiency;   MDS
    Interventions:   Procedure: Allogeneic HSC;   Drug: Busulfan Test dose;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Leukemia
    Intervention:   Drug: BAY2402234
    Sponsor:   Bayer
    Recruiting

  • Conditions:   Hematologic Malignancies;   Inborn Errors of Metabolism Disorders;   Immune Deficiencies
    Intervention:   Biological: CliniMACS CD34 Reagent System
    Sponsors:   Joanne Kurtzberg, MD;   Duke University;   Miltenyi Biotec, Inc.
    Available

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Fludarabine;   Drug: Cytoxan;   Radiation: Total Body Irradiation;   Procedure: Allogeneic Blood or Marrow Transplant;   Procedure: Peripheral Blood Stem Cell Transplant;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Solid Tumors and Hematologic Malignancy
    Interventions:   Drug: INCB059872;   Drug: all-trans retinoic acid (ATRA);   Drug: azacitidine;   Drug: nivolumab
    Sponsor:   Incyte Corporation
    Recruiting

  • Condition:   Paroxysmal Nocturnal Hemoglobinuria
    Interventions:   Drug: APL-2;   Drug: Soliris
    Sponsor:   Apellis Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Intervention:   Biological: ALXN1210
    Sponsor:   Alexion Pharmaceuticals
    Recruiting

  • Condition:   Paroxysmal Nocturnal Hemoglobinuria
    Interventions:   Drug: ABP 959;   Drug: Eculizumab
    Sponsor:   Amgen
    Recruiting

  • Condition:   Solid Tumors
    Interventions:   Drug: INCB053914;   Drug: I-DAC (Intermediate dose cytarabine);   Drug: Azacitidine;   Drug: Ruxolitinib
    Sponsor:   Incyte Corporation
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Itacitinib;   Drug: Calcineurin inhibitor
    Sponsor:   Incyte Corporation
    Recruiting